Joint ventures and strategic alliances can facilitate a company’s ability to react to dynamic business environments and to successfully achieve critical business objectives. While they can be notoriously difficult to structure and negotiate, working with skilled advisors of joint ventures law is a critical first step in ensuring the potential for success.
Our lawyers have deep experience in drafting joint venture and strategic alliance agreements. We regularly assist clients in planning and executing complex consolidations and disaffiliations of businesses and mission-critical systems. We also are well versed in helping clients to create new lines of business and revolutionize old ones. With many successful projects to our credit, our clients have come to rely on us as trusted advisors in the structuring and success of these ventures.
We are highly skilled in bringing together parties with diverse strengths and common goals. We assist clients in structuring the ownership entity, advise on the relevant tax implications, and negotiate and draft all related documents, including LLC and partnership agreements. In particular, we have developed an expertise in Delaware limited liability company law, the law sophisticated investors typically use for joint ventures. We are experts in the securities laws governing capital raising activities for joint ventures, including the pending crowdfunding and Reg D advertising rulemaking arising from the recently passed federal JOBS Act.
We work with our Tax lawyers to address income allocation issues and, when disputes arise between joint venture parties, we work with our Litigation attorneys to efficiently litigate and/or resolve fiduciary duty, tax and other joint venture legal issues.
Resources on our website for joint venture law include:
- Delaware vs. New York LLC - our Client Alert on the advantages of using a Delaware LLC
- LLC Agreement Questions - our LLC checklist in the form of questions to clients
-
$76 Million Acquisition of Pharmaceutical Company
We represented Footstar, Inc. in connection with the formation of a joint venture to facilitate the acquisition of CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX), a specialty pharmaceutical company, in a transaction valued at approximately $76 million. The transaction was financed through a combination of equity and debt.
